Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40

被引：1
|
作者：
Langley, Richard G. [1 ]
Sanyal, Chiranjeev [2 ,3 ]
Situ, Aaron [3 ,4 ]
Alulis, Sarah [5 ]
Hassan, Fareen [6 ]
Peterson, Steve [7 ]
Teneralli, Rachel E. [7 ]
Lee, Jennifer [5 ]
Patel, Barkha P. [3 ]
Disher, Tim [3 ]
机构：
[1] Dalhousie Univ, Dept Med, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
[2] Dalhousie Univ, Coll Pharm, Dept Community Hlth & Epidemiol, Halifax, NS, Canada
[3] CRGEVERSANA, Value & Evidence Serv, Burlington, ON, Canada
[4] Tigermed BDM, Somerset, NJ USA
[5] Janssen Cilag AS, Birkerod, Denmark
[6] Janssen Cilag Ltd, High Wycombe, England
[7] Janssen Immunol Global Commercial Strategy Org, Horsham, PA USA
来源：
JAAD INTERNATIONAL | 2024年 / 15卷
关键词：
change from baseline; guselkumab; indirect treatment comparisons; matching-adjusted indirect comparison; risankizumab; PASI;
D O I：
10.1016/j.jdin.2023.12.012
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：165 / 167
页数：3
相关论文
共 30 条
  • [1] Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
    Armstrong, April W.
    Soliman, Ahmed M.
    Gisondi, Paolo
    Fang, Siran
    Patel, Manish
    Strober, Bruce
    DERMATOLOGY AND THERAPY, 2024, 14 (11) : 3071 - 3081
  • [2] Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
    Hampton, Philip
    Borg, Emma
    Hansen, Jes Birger
    Augustin, Matthias
    PSORIASIS-TARGETS AND THERAPY, 2021, 11 : 123 - 131
  • [3] Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics
    Kim, Tae-Rim
    Won, Yumi
    Kim, Yeona
    Won, Sang-Hyeon
    Bae, Kyung-Nam
    Lee, Jungsoo
    Shin, Kihyuk
    Kim, Hoonsoo
    Ko, Hyunchang
    Kim, Moon-Bum
    Kim, Byungsoo
    EUROPEAN JOURNAL OF DERMATOLOGY, 2023, 33 (05) : 518 - 523
  • [4] Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China
    Huang, He
    Liu, Hao
    Zhu, Zhengwei
    Wang, Wenjun
    Liang, Bo
    Tang, Huayang
    Yang, Sen
    Sheng, Yujun
    Sun, Liangdan
    Zhang, Xuejun
    EUROPEAN JOURNAL OF DERMATOLOGY, 2024, 34 (01) : 73 - 78
  • [5] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Edwards, Christopher J.
    Sawant, Ruta
    Garg, Vishvas
    Du, Ella X.
    Friedman, Alan
    Betts, Keith A.
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 167 - 181
  • [6] A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
    Christopher J. Edwards
    Ruta Sawant
    Vishvas Garg
    Ella X. Du
    Alan Friedman
    Keith A. Betts
    Rheumatology and Therapy, 2021, 8 : 167 - 181
  • [7] Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
    Blauvelt, Andrew
    Armstrong, April W.
    Langley, Richard G.
    Gebauer, Kurt
    Thaci, Diamant
    Bagel, Jerry
    Guenther, Lyn C.
    Paul, Carle
    Randazzo, Bruce
    Flavin, Susan
    Hsu, Ming-Chun
    You, Yin
    Reich, Kristian
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (04) : 2317 - 2324
  • [8] Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Torres, Tiago
    Petersen, Anne Sohrt
    Ivens, Ulla
    Vilaro, Albert Bosch
    Stinson, John
    Carrascosa, Jose Manuel
    DERMATOLOGY AND THERAPY, 2024, 14 (04) : 983 - 992
  • [9] Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
    Borroni, Riccardo G.
    Malagoli, Piergiorgio
    Gargiulo, Luigi
    Valenti, Mario
    Pavia, Giulia
    Facheris, Paola
    Morenghi, Emanuela
    Di Corteranzo, Isotta Giunipero
    Narcisi, Alessandra
    Ortoncelli, Michela
    Dapavo, Paolo
    Costanzo, Antonio
    ACTA DERMATO-VENEREOLOGICA, 2021, 101
  • [10] Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study
    Rompoti, Natalia
    Koumprentziotis, Ioannis-Alexios
    Stefanaki, Irene
    Vavouli, Charitomeni
    Papoutsaki, Marina
    Politou, Maria
    Panagakis, Pantelis
    Befon, Angeliki
    Kousta, Fiori
    Lazou, Eleni
    Chasapi, Vasiliki
    Stratigos, Alexander
    Nicolaidou, Electra
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (09)
123